Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model - Quiz - MDSpire

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • By

  • Sumit Bhattacharyya

  • Insug O-Sullivan

  • Joanne K. Tobacman

  • June 1, 2026

  • 0 min

Share

Original Source(s)

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • by Sumit Bhattacharyya, Insug O-Sullivan, Joanne K. Tobacman

  • June 1, 2026

Related Content

Unmasking the “targetless” illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade